ENDRA Life Sciences Inc. S-8, filed Mar 26, 2020: FORM S-8
As
filed with the Securities and Exchange Commission on March 26,
2020
Registration
No.
333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF
1933
ENDRA LIFE SCIENCES INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
26-0579295
|
|
(State
or other jurisdiction of incorporation or
organization)
|
(I.R.S.
Employer Identification No.)
|
|
3600 Green Court, Suite 350
Ann Arbor, MI
|
48105
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
ENDRA Life Sciences Inc. 2016 Omnibus Incentive Plan
(Full
title of the plan)
Francois Michelon
Chief Executive Officer
ENDRA Life Sciences Inc.
3600 Green Court, Suite 350
Ann Arbor, MI 48105
(Name
and address of agent for service)
(734) 335-0468
(Telephone
number, including area code,
of
agent for service)
Indicate by check
mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of
“large accelerated filer,” “accelerated
filer,” “smaller reporting company” and
“emerging growth company” in Rule 12b-2 of the Exchange
Act.
|
Large
accelerated filer
|
☐
|
|
Accelerated
filer
|
☐
|
|
Non-accelerated
filer
|
☑
|
|
Smaller
reporting company
|
☑
|
|
|
|
|
Emerging
growth company
|
☑
|
If an emerging
growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying
with any new or revised financial accounting standards pursuant to
Section 7(a)(2)(B) of the Securities Act. □
CALCULATION OF
REGISTRATION FEE
|
Title
of Securities to
be
Registered
|
Amount
to
be
Registered
(1)
|
Proposed
Maximum
Offering
Price
Per Share
(2)
|
Proposed
Maximum
Aggregate
Offering
Price
|
Amount
of
Registration
Fee
|
|
Common Stock,
$0.0001 par value per share, to be issued under the
Registrant’s 2016 Omnibus Incentive Plan
|
3,202,280(3)
|
$0.79
|
$2,529,801
|
$329
|
(1) In
addition, pursuant to Rule 416(a), this Registration Statement also
covers such indeterminate number of additional shares of Common
Stock as is necessary to eliminate any dilutive effect of any
future stock split, stock dividend or similar
transaction.
(2)
Estimated solely for the purpose of calculating the registration
fee pursuant to Rule 457(c) and 457(h) of the Securities Act of
1933, as amended, and based on the average of the high and low
prices for the Registrant’s Common Stock on March 19, 2020,
as reported on The Nasdaq Capital Market.
(3)
Represents 3,202,280 additional shares of Common Stock that were
automatically added to the shares authorized for issuance
under the Registrant’s 2016 Omnibus Incentive Plan, as
amended (the “Plan”), on January 1, 2020 pursuant to an
annual “evergreen” increase provision contained in the
Plan. Pursuant to such provision, the number of shares reserved for
issuance under the Plan
automatically increases on each January 1 by
the lesser of (a) the number of shares necessary such that the
aggregate number of shares available under the Plan equals 25% of
the number of fully-diluted outstanding shares on the increase date
(assuming the conversion of all outstanding shares of preferred
stock and other outstanding convertible securities and the exercise
of all outstanding options and warrants to purchase shares), and
(b) a number of shares determined by the Registrant’s board
of directors.
2
EXPLANATORY NOTE
This
Registration Statement on Form S-8 is being filed to register an
additional 3,202,280 shares of Common Stock under the ENDRA Life
Sciences Inc. 2016 Omnibus Incentive Plan, as amended (the
“Plan”), as a result of an evergreen provision in the
Plan providing that the total number of shares of Common Stock
reserved for issuance under the Plan is automatically increased as
of each January 1.
These
additional shares of Common Stock are securities of the same class
as other securities for which the Registration Statements on Form
S-8 (File Nos. 333-218894 and 333-233178) (the “Prior
Registration Statements”) were filed with the Securities and
Exchange Commission (the “Commission”) on June 21, 2017
and August 9, 2019, respectively. In accordance with Instruction E
of Form S-8, the content of the Prior Registration Statements are
incorporated herein by reference and made a part of this
Registration Statement on Form S-8.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
Item
1. Plan Information.
The
information required by this Item 1 is omitted from this
registration statement in accordance with Rule 428(b)(1) of the
Securities Act of 1933, as amended (the “Securities
Act”), and the Note to Part I of Form S-8.
Item
2. Registrant Information and Employee Plan Annual
Information.
The
information required by this Item 2 is omitted from this
registration statement in accordance with Rule 428(b)(1) of the
Securities Act and the Note to Part I of Form S-8.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item
3. Incorporation of Documents by Reference.
The
following documents have been filed by ENDRA Life Sciences Inc.
(the “Registrant”) with the Commission and are
incorporated herein by reference:
●
Annual Report on
Form 10-K for the fiscal year ended December 31, 2019, filed with
the Commission on March 26, 2020;
●
Current Reports on
Form 8-K, filed with the Commission on January 15, 2020 and March
10, 2020; and
3
●
The description of
the Registrant’s Common Stock contained in the
Registrant’s Registration Statement on Form S-1, originally
filed with the Commission on November 21, 2016, as amended (No.
333-214724), which description is incorporated by reference into
the Registrant’s Registration Statement on Form 8-A,
originally filed with the Commission pursuant to Section 12(g) of
the Exchange Act on December 16, 2016 (No. 001-37969), including
any further amendment or report filed hereafter for the purpose of
updating such description.
All
reports and other documents filed by the Registrant pursuant to
Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the
date hereof, and prior to the filing of a post-effective amendment
which indicates that all securities offered hereby have been sold
or which deregisters all securities then remaining unsold, shall be
deemed to be incorporated by reference herein and to be part hereof
from the date of filing of such reports and documents. The
Registrant is not incorporating by reference any reports or
documents or portions thereof that are not considered to be
“filed” with the Commission.
Any
statement contained herein or in a document incorporated or deemed
to be incorporated herein by reference shall be deemed to be
modified or superseded for purposes of this Registration Statement
to the extent that a statement contained herein or in any other
subsequently filed document which also is or is deemed to be
incorporated herein by reference modifies or supersedes such
earlier statement. Any statement so modified or superseded shall
not be deemed, except as so modified or superseded, to constitute a
part of this Registration Statement.
Item
8. Exhibits.
Exhibit
Number
Description
Fourth Amended and
Restated Certificate of Incorporation of ENDRA Life Sciences Inc.
(incorporated by reference to Exhibit 3.2 to the Registrant’s
Current Report on Form 8-K filed on May 12, 2017)
Amended and
Restated Bylaws of ENDRA Life Sciences Inc. (incorporated by
reference to Exhibit 3.4 to Amendment No. 1 to the
Registrant’s Registration Statement on Form S-1 (File No.
333-214724) filed on December 6, 2016)
ENDRA Life
Sciences Inc. 2016 Omnibus Incentive Plan (incorporated by
reference to Exhibit 10.4 to Amendment No. 1 to the
Registrant’s Registration Statement on Form S-1 (File No.
333-214724) filed on December 6, 2016)
First Amendment to
ENDRA Life Sciences Inc. 2016 Omnibus Incentive Plan (incorporated
by reference to Appendix A to the Registrant’s Definitive
Proxy Statement filed on May 10, 2018)
Form of Stock
Option Award under ENDRA Life Sciences Inc. 2016 Omnibus Incentive
Plan (incorporated by reference to Exhibit 10.5 to Amendment No. 1
to the Registrant’s Registration Statement on Form S-1 (File
No. 333-214724) filed on December 6, 2016)
Form of Restricted
Stock Unit Award under ENDRA Life Sciences Inc. 2016 Omnibus
Incentive Plan (incorporated by reference to Exhibit 10.6 to
Amendment No. 1 to the Registrant’s Registration Statement on
Form S-1 (File No. 333-214724) filed on December 6,
2016)
4
Opinion of K&L
Gates LLP
Consent of RBSM
LLP, Independent Registered Public Accounting Firm
Consent of K&L
Gates LLP (contained in Exhibit 5.1)
Power of Attorney
(included on the signature page of this Registration
Statement)
5
SIGNATURES
Pursuant to the
requirements of the Securities Act, the Registrant certifies that
it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-8 and has duly caused this
Registration Statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Ann Arbor,
State of Michigan, on March 26, 2020.
|
|
ENDRA Life Sciences
Inc.
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Francois
Michelon
|
|
|
|
|
Francois
Michelon
|
|
|
|
|
Chief Executive
Officer
|
|
POWER OF ATTORNEY
Each
person whose signature appears below constitutes and appoints
Francois Michelon and David R. Wells, and each of them, his true
and lawful attorney-in-fact and agent, each with full power of
substitution and resubstitution, severally, for him and in his
name, place and stead, in any and all capacities, to sign any and
all amendments (including post-effective amendments) to this
Registration Statement on Form S-8, and to file the same, with all
exhibits thereto and other documents in connection therewith, with
the Securities and Exchange Commission, granting unto said
attorneys-in-fact and agents, and each of them, full power and
authority to do and perform each and every act and thing requisite
and necessary to be done in and about the premises, as fully to all
intents and purposes as he might or could do in person, hereby
ratifying and confirming all that said attorneys-in-fact and
agents, or any of them or their or his or her substitute or
substitutes, may lawfully do or cause to be done by virtue hereof.
This power of attorney may be executed in
counterparts.
Pursuant to the requirements of the Securities
Act, this Registration Statement has been signed below by the
following persons in the capacities indicated, in each case
on March 26, 2020:
|
Signature
|
|
Title
|
|
/s/
Francois
Michelon
|
|
Chief
Executive Officer and Director
|
|
Francois
Michelon
|
|
(Principal
Executive Officer)
|
|
|
|
|
|
/s/
David R. Wells
|
|
Chief
Financial Officer
|
|
David
R. Wells
|
|
(Principal
Financial Officer and Principle Accounting Officer)
|
|
|
|
|
|
/s/
Anthony DiGiandomenico
|
|
Director
|
|
Anthony
DiGiandomenico
|
|
|
|
|
|
|
|
/s/
Michael Harsh
|
|
Director
|
|
Michael
Harsh
|
|
|
|
|
|
|
|
/s/
Alexander
Tokman
|
|
Director
|
|
Alexander
Tokman
|
|
|
6